Quantcast

In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes.

Research paper by Diane M DM Citron, Kerin L KL Tyrrell, Vreni V Merriam, Ellie J C EJ Goldstein

Indexed on: 04 May '11Published on: 04 May '11Published in: Antimicrobial agents and chemotherapy



Abstract

NXL104, a novel β-lactamase inhibitor, was tested at a constant concentration of 4 μg/ml in combination with ceftazidime (CAZ), with and without added metronidazole, against 396 β-lactamase-producing strains of anaerobic bacteria. MIC(50)/MIC(90) values for Bacteroides fragilis and the B. fragilis group were 8/16 and 64/>128 μg/ml, respectively. Although CAZ-NXL104 had limited activity against most anaerobic strains, in combination with metronidazole it shows potential for treating mixed infections involving resistant Enterobacteriaceae and anaerobes.